Clene (CLNN) Total Non-Current Liabilities (2020 - 2026)
Clene (CLNN) posted Total Non-Current Liabilities of $31.7 million for Q2 2026, up 3.33% on a QoQ basis from $30.7 million in Q4 2025, and up 12.63% year-over-year from $28.1 million in Q2 2025.
Analysis
Clene (CLNN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Clene has reported Total Non-Current Liabilities for 7 years, with the latest figure at $31.7 million in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 12.63% year-over-year to $31.7 million in Q2 2026; TTM through Jun 2026 was $31.7 million, a 12.63% increase from a year earlier, with the FY2025 full-year figure at $30.7 million, down 3.14% from the prior year.
- Total Non-Current Liabilities was $31.7 million for Q2 2026 at Clene, up from $30.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $41.3 million in Q4 2022, with the low at $28.1 million in Q2 2025.
- Average Total Non-Current Liabilities over 5 years is $34.6 million, with a median of $35.1 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities increased 18.26% in 2023, then decreased 28.99% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $41.3 million in 2022, then fell by 9.18% to $37.5 million in 2023, then retreated by 15.52% to $31.7 million in 2024, then decreased by 3.14% to $30.7 million in 2025, then advanced by 3.33% to $31.7 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $31.7 million (Q2 2026), $30.7 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 1.53 Bn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Clene | 45.69 Mn | 45.69 Mn | 54,000.00 | 31.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.68 Mn |
| Dec 31, 2025 | 30.66 Mn |
| Sep 30, 2025 | 30.39 Mn |
| Jun 30, 2025 | 28.13 Mn |
| Mar 31, 2025 | 28.26 Mn |
| Dec 31, 2024 | 31.65 Mn |
| Sep 30, 2024 | 35.10 Mn |
| Jun 30, 2024 | 39.61 Mn |
| Mar 31, 2024 | 38.02 Mn |
| Dec 31, 2023 | 37.47 Mn |
| Sep 30, 2023 | 37.17 Mn |
| Jun 30, 2023 | 38.11 Mn |
| Mar 31, 2023 | 39.20 Mn |
| Dec 31, 2022 | 41.26 Mn |
| Sep 30, 2022 | 33.89 Mn |
| Jun 30, 2022 | 35.26 Mn |
| Mar 31, 2022 | 33.14 Mn |
| Dec 31, 2021 | 49.99 Mn |
| Sep 30, 2021 | 33.37 Mn |
| Jun 30, 2021 | 30.19 Mn |